Dose-Escalation of Octreotide-LAR in Patients With Neuroendocrine Tumors (NET)

被引：0
|
作者：
Kulke, Matthew H. [1 ]
Strosberg, Jonathan R. [2 ]
Lynn Huynh [3 ]
Mei Sheng Duh [3 ]
Sahai, Vaibhav [4 ]
Rademaker, Alfred W. [4 ]
Benson, Al B. [4 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept GI Oncol, Tampa, FL USA
[3] Anal Grp Inc, Boston, MA USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
PANCREAS | 2014年 / 43卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：497 / 497
页数：1
相关论文
共 50 条
  • [1] Effect of dose intensification (DI) of octreotide-LAR (O-LAR) among symptomatic patients with neuroendocrine tumors (NETs)
    Al Efraij, Khalid S.
    Aljama, Mohammed A.
    Kennecke, Hagen F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [2] Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR:A systematic literature review
    Michael S Broder
    David Beenhouwer
    Jonathan R Strosberg
    Maureen P Neary
    Dasha Cherepanov
    World Journal of Gastroenterology, 2015, (06) : 1945 - 1955
  • [3] Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review
    Broder, Michael S.
    Beenhouwer, David
    Strosberg, Jonathan R.
    Neary, Maureen P.
    Cherepanov, Dasha
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (06) : 1945 - 1955
  • [4] Phase I dose-escalation study of pasireotide LAR in patients with advanced neuroendocrine tumors.
    Phan, Alexandria T.
    Wolin, Edward M.
    Chan, Jennifer A.
    Huang, Jerry M.
    Hudson, Michelle
    Hughes, Gareth
    Shen, Guoxiang
    Strosberg, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly
    Colao, Annamaria
    Pivonello, Rosario
    Auriemma, Renata S.
    Galdiero, Mariano
    Savastano, Silvia
    Lombardi, Gaetano
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 157 (05) : 579 - 587
  • [6] Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors
    Woltering, EA
    Mamikunian, PM
    Zietz, S
    Krutzik, SR
    Go, VLW
    Vinik, AI
    Vinik, E
    O'Dorisio, TM
    Mamikunian, G
    PANCREAS, 2005, 31 (04) : 392 - 400
  • [7] Above Standard Dose of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET) for Control of Carcinoid Syndrome Symptoms: A Multi-Center Retrospective Chart Review Study
    Strosberg, Jonathan R.
    Benson, Al B.
    Huynh, Lynn
    Duh, Mei Sheng
    Goldman, Jamie
    Sahai, Vaibhav
    Rademaker, Alfred W.
    Kulke, Matthew H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 253 - 254
  • [8] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [9] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Octreotide LAR works for neuroendocrine Tumors
    Rohrmoser, L.
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2009, 2 (03): : 31 - 32
12345